<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528706</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2-02</org_study_id>
    <nct_id>NCT04528706</nct_id>
  </id_info>
  <brief_title>A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)</brief_title>
  <acronym>NEXUS</acronym>
  <official_title>An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minoryx Therapeutics, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minoryx Therapeutics, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, multicenter study in male pediatric patients with cerebral x-linked&#xD;
      adrenoleukodystrophy (cald) to assess the effects of MIN-102 treatment on disease progression&#xD;
      prior to human stem cell transplant (HSCT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate whether MIN-102 can halt disease progression of cALD if administered prior to hematopoietic stem-cell transplantation (HSCT), as determined by serial clinical and MRI investigations in pediatric subjects.</measure>
    <time_frame>6 months- 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>&quot;arrested disease&quot; will be assessed at 24 weeks and at 96 weeks</measure>
    <time_frame>at 24 weeks and 96 weeks</time_frame>
    <description>arrested disease is defined using: Cahnge in NFS from Baseline, Free of MFD and lack of lesion progression on MRI</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Cerebral Adrenoleukodystrophy</condition>
  <arm_group>
    <arm_group_label>MIN-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIN-102</intervention_name>
    <description>Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.</description>
    <arm_group_label>MIN-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged ≥2 and ≤12 years with a diagnosis of X-linked ALD&#xD;
&#xD;
          -  White matter involvement as determined by cerebral MRI lesions without Gd enhancement&#xD;
             at baseline (Population 1), or with Gd enhancement at baseline (Population 2).&#xD;
&#xD;
          -  Major Functional Disabilities (MFD) score of 0.&#xD;
&#xD;
          -  Baseline Loes score &gt;0 and ≤10&#xD;
&#xD;
          -  Gadolinium Intensity Score &gt;2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous HSCT&#xD;
&#xD;
          -  Too far progressed inflammatory brain lesions&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uwe Meya</last_name>
    <phone>+34 93 544 14 66</phone>
    <email>info@minoryx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Carolin Sevine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Hendrik Rosewich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Annette Bley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Maria Angeles García Cazorla</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

